Paradoxical SAPHO syndrome observed during anti-TNF-α therapy for Crohn's disease

Hitoshi Amano,1 Reikei Matsuda,1 Tomohiko Shibata,2 Daisuke Takahashi,1 Shinichiro Suzuki3 1Department of Gastroenterology, Fujisawa Shonandai Hospital, Fujisawa, 2Division of Rheumatology, Department of Internal Medicine, St Marianna University School of Medicine, Yokohama City Seibu Hospital, Yoko...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Amano H, Matsuda R, Shibata T, Takahashi D, Suzuki S
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2017
Materias:
Acceso en línea:https://doaj.org/article/6d7ce30949364659b6121d8a0ea7d447
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:6d7ce30949364659b6121d8a0ea7d447
record_format dspace
spelling oai:doaj.org-article:6d7ce30949364659b6121d8a0ea7d4472021-12-02T03:57:26ZParadoxical SAPHO syndrome observed during anti-TNF-α therapy for Crohn's disease1177-5491https://doaj.org/article/6d7ce30949364659b6121d8a0ea7d4472017-05-01T00:00:00Zhttps://www.dovepress.com/paradoxical-sapho-syndrome-observed-during-anti-tnf-alpha-therapy-for--peer-reviewed-article-BTThttps://doaj.org/toc/1177-5491Hitoshi Amano,1 Reikei Matsuda,1 Tomohiko Shibata,2 Daisuke Takahashi,1 Shinichiro Suzuki3 1Department of Gastroenterology, Fujisawa Shonandai Hospital, Fujisawa, 2Division of Rheumatology, Department of Internal Medicine, St Marianna University School of Medicine, Yokohama City Seibu Hospital, Yokohama, 3Department of Surgery, Fujisawa Shonandai Hospital, Fujisawa, Japan Abstract: Currently, anti-TNFα antibodies are used to treat Crohn’s disease. We report on a 45-year-old Japanese female with Crohn’s disease developing SAPHO (synovitis, acne, pustulosis, hyperostosis, and osteitis) syndrome following exposure to the anti-TNFα antibody adalimumab. Initially, adalimumab induced remission, but the patient showed SAPHO syndrome 11 weeks following the start of adalimumab therapy for the first time. Cutaneous and articular involvement were exacerbating the condition, so adalimumab was discontinued and the patient was put on low-dose methotrexate to control her symptoms. To our knowledge, this is the first report of SAPHO syndrome occurring during anti-TNF therapy, which is thought to be a paradoxical response to adalimumab. Keywords: anti-TNFα, adalimumab, paradoxical reaction, SAPHO syndrome, Crohn’s diseaseAmano HMatsuda RShibata TTakahashi DSuzuki SDove Medical PressarticleSAPHO syndromeparadoxical reactionCrohn diseaseanti-TNF-α therapyadalimumabMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol Volume 11, Pp 65-69 (2017)
institution DOAJ
collection DOAJ
language EN
topic SAPHO syndrome
paradoxical reaction
Crohn disease
anti-TNF-α therapy
adalimumab
Medicine (General)
R5-920
spellingShingle SAPHO syndrome
paradoxical reaction
Crohn disease
anti-TNF-α therapy
adalimumab
Medicine (General)
R5-920
Amano H
Matsuda R
Shibata T
Takahashi D
Suzuki S
Paradoxical SAPHO syndrome observed during anti-TNF-α therapy for Crohn's disease
description Hitoshi Amano,1 Reikei Matsuda,1 Tomohiko Shibata,2 Daisuke Takahashi,1 Shinichiro Suzuki3 1Department of Gastroenterology, Fujisawa Shonandai Hospital, Fujisawa, 2Division of Rheumatology, Department of Internal Medicine, St Marianna University School of Medicine, Yokohama City Seibu Hospital, Yokohama, 3Department of Surgery, Fujisawa Shonandai Hospital, Fujisawa, Japan Abstract: Currently, anti-TNFα antibodies are used to treat Crohn’s disease. We report on a 45-year-old Japanese female with Crohn’s disease developing SAPHO (synovitis, acne, pustulosis, hyperostosis, and osteitis) syndrome following exposure to the anti-TNFα antibody adalimumab. Initially, adalimumab induced remission, but the patient showed SAPHO syndrome 11 weeks following the start of adalimumab therapy for the first time. Cutaneous and articular involvement were exacerbating the condition, so adalimumab was discontinued and the patient was put on low-dose methotrexate to control her symptoms. To our knowledge, this is the first report of SAPHO syndrome occurring during anti-TNF therapy, which is thought to be a paradoxical response to adalimumab. Keywords: anti-TNFα, adalimumab, paradoxical reaction, SAPHO syndrome, Crohn’s disease
format article
author Amano H
Matsuda R
Shibata T
Takahashi D
Suzuki S
author_facet Amano H
Matsuda R
Shibata T
Takahashi D
Suzuki S
author_sort Amano H
title Paradoxical SAPHO syndrome observed during anti-TNF-α therapy for Crohn's disease
title_short Paradoxical SAPHO syndrome observed during anti-TNF-α therapy for Crohn's disease
title_full Paradoxical SAPHO syndrome observed during anti-TNF-α therapy for Crohn's disease
title_fullStr Paradoxical SAPHO syndrome observed during anti-TNF-α therapy for Crohn's disease
title_full_unstemmed Paradoxical SAPHO syndrome observed during anti-TNF-α therapy for Crohn's disease
title_sort paradoxical sapho syndrome observed during anti-tnf-α therapy for crohn's disease
publisher Dove Medical Press
publishDate 2017
url https://doaj.org/article/6d7ce30949364659b6121d8a0ea7d447
work_keys_str_mv AT amanoh paradoxicalsaphosyndromeobservedduringantitnfalphatherapyforcrohn39sdisease
AT matsudar paradoxicalsaphosyndromeobservedduringantitnfalphatherapyforcrohn39sdisease
AT shibatat paradoxicalsaphosyndromeobservedduringantitnfalphatherapyforcrohn39sdisease
AT takahashid paradoxicalsaphosyndromeobservedduringantitnfalphatherapyforcrohn39sdisease
AT suzukis paradoxicalsaphosyndromeobservedduringantitnfalphatherapyforcrohn39sdisease
_version_ 1718401555852427264